scholarly article | Q13442814 |
P819 | ADS bibcode | 2017PLoSO..1270362A |
P356 | DOI | 10.1371/JOURNAL.PONE.0170362 |
P932 | PMC publication ID | 5256915 |
P698 | PubMed publication ID | 28114428 |
P2093 | author name string | Hyo Jun Ahn | |
Seung Kew Yoon | |||
Jong Young Choi | |||
Jeong Won Jang | |||
Myeong Jun Song | |||
Si Hyun Bae | |||
P2860 | cites work | Response to tenofovir monotherapy in chronic hepatitis B patients with prior suboptimal response to entecavir. | Q53664727 |
Tenofovir disoproxil fumarate rescue therapy following failure of both lamivudine and adefovir dipivoxil in chronic hepatitis B | Q82240888 | ||
Efficacy and safety of tenofovir disoproxil fumarate in Asian-Americans with chronic hepatitis B in community settings | Q28540372 | ||
EASL clinical practice guidelines: Management of chronic hepatitis B virus infection | Q29615868 | ||
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide-naïve chronic hepatitis B patients in Korea: data from the clinical practice setting in a single-center cohort. | Q30860824 | ||
Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013. | Q30984322 | ||
Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level | Q34481474 | ||
Efficacy of entecavir-tenofovir combination therapy for chronic hepatitis B patients with multidrug-resistant strains | Q34596639 | ||
Long-term efficacy of tenofovir disoproxil fumarate therapy after multiple nucleos(t)ide analogue failure in chronic hepatitis B patients | Q34948124 | ||
Tenofovir disoproxil fumarate is superior to lamivudine plus adefovir in lamivudine-resistant chronic hepatitis B patients | Q35152367 | ||
Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients | Q35231822 | ||
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update | Q35706189 | ||
Risk Factors for Renal Functional Decline in Chronic Hepatitis B Patients Receiving Oral Antiviral Agents | Q36445048 | ||
Efficacy of tenofovir in patients with Lamivudine failure is not different from that in nucleoside/nucleotide analogue-naive patients with chronic hepatitis B. | Q36757579 | ||
Hepatitis B today. | Q36830925 | ||
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year, Prospective, Real-World Study in France | Q37250436 | ||
Hepatitis B virus genotype C prevails among chronic carriers of the virus in Korea | Q37425698 | ||
Long-term therapy with nucleoside/nucleotide analogues for chronic hepatitis B in Asian patients | Q38062304 | ||
Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir disoproxil fumarate in patients with lamivudine-resistant chronic hepatitis B. | Q39014100 | ||
Effectiveness and Safety of Tenofovir Disoproxil Fumarate in Chronic Hepatitis B: A 3-Year Prospective Field Practice Study in Germany | Q40313106 | ||
Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection. | Q40543517 | ||
Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naïve and nucleos(t)ide analog-experienced chronic hepatitis B patients | Q40835942 | ||
Entecavir plus tenofovir combination therapy in patients with multidrug-resistant chronic hepatitis B: results of a multicentre, prospective study. | Q40967783 | ||
Prediction of virologic response to tenofovir mono-rescue therapy for multidrug resistant chronic hepatitis B. | Q41148991 | ||
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. | Q41175515 | ||
Efficacy and safety of tenofovir in nucleos(t)ide-naïve patients with genotype C chronic hepatitis B in real-life practice | Q41367567 | ||
Tenofovir-associated Fanconi syndrome and nephrotic syndrome in a patient with chronic hepatitis B monoinfection | Q41507823 | ||
Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. | Q41538789 | ||
Efficacy of Tenofovir-based Rescue Therapy in Lamivudine-resistant Chronic Hepatitis B Patients With Failure of Lamivudine and Adefovir Combination. | Q41752080 | ||
Tenofovir-based rescue therapy in chronic hepatitis B patients with suboptimal responses to adefovir with prior lamivudine resistance | Q42144275 | ||
Long-term efficacy and safety of emtricitabine plus tenofovir DF vs. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. | Q42251695 | ||
Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. | Q42678962 | ||
Long-term efficacy of tenofovir monotherapy for hepatitis B virus-monoinfected patients after failure of nucleoside/nucleotide analogues | Q43226767 | ||
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice | Q43445015 | ||
Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil | Q43607727 | ||
Predicting cirrhosis risk based on the level of circulating hepatitis B viral load | Q46985831 | ||
P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
P6216 | copyright status | copyrighted | Q50423863 |
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | tenofovir | Q155954 |
chronic hepatitis B | Q55779876 | ||
chronic hepatitis | Q62019625 | ||
P304 | page(s) | e0170362 | |
P577 | publication date | 2017-01-23 | |
P1433 | published in | PLOS One | Q564954 |
P1476 | title | Treatment Efficacy and Safety of Tenofovir-Based Therapy in Chronic Hepatitis B: A Real Life Cohort Study in Korea | |
P478 | volume | 12 |
Q59340545 | Chronic hepatitis B genotype E in African migrants: response to nucleos(t)ide treatment in real clinical practice |
Q59351826 | Evaluation of drug resistance mutations in patients with chronic hepatitis B |
Q58596648 | Treatment Outcome and Renal Safety of 3-Year Tenofovir Disoproxil Fumarate Therapy in Chronic Hepatitis B Patients with Preserved Glomerular Filtration Rate |
Search more.